Literature DB >> 24482036

Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

Alexander Baraniskin1, Stefanie Nöpel-Dünnebacke, Brigitte Schumacher, Christian Gerges, Thilo Bracht, Barbara Sitek, Helmut E Meyer, Guido Gerken, Alexander Dechene, Jörg F Schlaak, Roland Schroers, Christian Pox, Wolff Schmiegel, Stephan A Hahn.   

Abstract

BACKGROUND AND OBJECTIVES: Up to now the diagnosis of early stage cholangiocarcinoma (CC) has remained difficult, with low sensitivities reported for current diagnostic methods. Based on recent promising findings about circulating U2 small nuclear RNA fragments (RNU2-1f) as novel blood-based biomarkers for pancreatic and colorectal adenocarcinoma, we studied the utility of RNU2-1f as a diagnostic marker of CC in bile fluid.
METHODS: Bile fluid was collected from patients with CC (n = 12), controls (patients with choledocholithiasis) (n = 11) and with primary sclerosing cholangitis (PSC; n = 11). RNU2-1f levels were measured by real-time polymerase chain reaction normalized to cel-54.
RESULTS: Measurement of RNU2-1f levels in bile fluids enabled the differentiation of patients with CC from controls in all cases. Furthermore, RNU2-1f levels in bile fluids of patients with CC were significantly higher than in patients with PSC, resulting in a receiver-operating characteristic curve area of 0.856, with sensitivity of 67 % and specificity of 91 %.
CONCLUSIONS: Our data suggest that the measurement of RNU2-1 fragments detected in the bile fluid can be used as a diagnostic marker for CC and should be included in future prospective diagnostic studies for this disease entity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24482036     DOI: 10.1007/s10620-014-3034-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Authors:  A H Patel; D M Harnois; G G Klee; N F LaRusso; G J Gores
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma.

Authors:  Yongjun Chen; Jian Luo; Rui Tian; Huawen Sun; Shengquan Zou
Journal:  Dig Dis Sci       Date:  2010-11-18       Impact factor: 3.199

3.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

4.  Incidence of benign pathology in patients undergoing hepatic resection for suspected malignancy.

Authors:  R A E Clayton; D L Clarke; E J Currie; K K Madhavan; R W Parks; O J Garden
Journal:  Surgeon       Date:  2003-02       Impact factor: 2.392

5.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.

Authors:  Jason D Arroyo; John R Chevillet; Evan M Kroh; Ingrid K Ruf; Colin C Pritchard; Donald F Gibson; Patrick S Mitchell; Christopher F Bennett; Era L Pogosova-Agadjanyan; Derek L Stirewalt; Jonathan F Tait; Muneesh Tewari
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

Review 6.  The role of microRNAs in liver cancer.

Authors:  Ioannis Papaconstantinou; Andreas Karakatsanis; Maria Gazouli; George Polymeneas; Dionissios Voros
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-03       Impact factor: 2.566

7.  Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer.

Authors:  Michael H Chapman; Neomal S Sandanayake; Fausto Andreola; Dipok K Dhar; George J Webster; James S Dooley; Stephen P Pereira
Journal:  J Clin Exp Hepatol       Date:  2011-06

8.  MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin.

Authors:  Jinqiang Zhang; Chang Han; Tong Wu
Journal:  Gastroenterology       Date:  2012-04-03       Impact factor: 22.682

9.  MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3.

Authors:  Florin M Selaru; Alexandru V Olaru; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Jian Yang; Bogdan Paun; Zhe Jin; Rachana Agarwal; James P Hamilton; John Abraham; Christos Georgiades; Hector Alvarez; Perumal Vivekanandan; Wayne Yu; Anirban Maitra; Michael Torbenson; Paul J Thuluvath; Gregory J Gores; Nicholas F LaRusso; Ralph Hruban; Stephen J Meltzer
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

10.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

View more
  11 in total

1.  What is the current role of endoscopy in primary sclerosing cholangitis?

Authors:  Benjamin Tharian; Nayana Elizabeth George; Tony Chiew Keong Tham
Journal:  World J Gastrointest Endosc       Date:  2015-08-10

Review 2.  Molecular diagnosis of intrahepatic cholangiocarcinoma.

Authors:  Hiroaki Haga; Tushar Patel
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-09-29       Impact factor: 7.027

3.  Truncated forms of U2 snRNA (U2-tfs) are shunted toward a novel uridylylation pathway that differs from the degradation pathway for U1-tfs.

Authors:  Hideaki Ishikawa; Yuko Nobe; Keiichi Izumikawa; Masato Taoka; Yoshio Yamauchi; Hiroshi Nakayama; Richard J Simpson; Toshiaki Isobe; Nobuhiro Takahash
Journal:  RNA Biol       Date:  2017-12-15       Impact factor: 4.652

Review 4.  Extracellular RNA in aging.

Authors:  Douglas F Dluzen; Nicole Noren Hooten; Michele K Evans
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-08-17       Impact factor: 9.957

5.  Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

Authors:  Jens Köhler; Martin Schuler; Thomas Christoph Gauler; Stefanie Nöpel-Dünnebacke; Maike Ahrens; Andreas-Claudius Hoffmann; Stefan Kasper; Felix Nensa; Benedikt Gomez; Maria Hahnemann; Frank Breitenbuecher; Danjouma Cheufou; Filiz Özkan; Kaid Darwiche; Mathias Hoiczyk; Henning Reis; Stefan Welter; Wilfried Ernst Erich Eberhardt; Martin Eisenacher; Helmut Teschler; Georgios Stamatis; Wolff Schmiegel; Stephan Albrecht Hahn; Alexander Baraniskin
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-19       Impact factor: 4.553

Review 6.  Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.

Authors:  Fang Bao; Jiayue Liu; Haiyang Chen; Lu Miao; Zhaochao Xu; Guixin Zhang
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

7.  Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.

Authors:  Alexander Baraniskin; Elena Zaslavska; Stefanie Nöpel-Dünnebacke; Guido Ahle; Sabine Seidel; Uwe Schlegel; Wolff Schmiegel; Stephan Hahn; Roland Schroers
Journal:  Neuro Oncol       Date:  2015-08-06       Impact factor: 12.300

Review 8.  Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.

Authors:  Sumera Rizvi; John E Eaton; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2015-06-05       Impact factor: 11.382

Review 9.  Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.

Authors:  Barbara Pardini; Alexandru Anton Sabo; Giovanni Birolo; George Adrian Calin
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

Review 10.  Regulatory Roles of Non-Coding RNAs in Colorectal Cancer.

Authors:  Jun Wang; Yong-Xi Song; Bin Ma; Jia-Jun Wang; Jing-Xu Sun; Xiao-Wan Chen; Jun-Hua Zhao; Yu-Chong Yang; Zhen-Ning Wang
Journal:  Int J Mol Sci       Date:  2015-08-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.